Connect with us

Life Sciences

StuffThatWorks Ushers in a New Era of Patient-Pharma Communication with the Launch of StuffThatWorks for Life Sciences

Led by senior founding members of Waze, StuffThatWorks, the patient community platform that harnesses crowdsourcing and AI technology to empower people…

Published

on

This article was originally published by AITHORITY
StuffThatWorks Ushers in a New Era of Patient-Pharma Communication with the Launch of StuffThatWorks for Life Sciences

Led by senior founding members of Waze, StuffThatWorks, the patient community platform that harnesses crowdsourcing and AI technology to empower people dealing with chronic health conditions to better navigate their health, announced today the expansion of its digital health platform with the launch of StuffThatWorks for Life Sciences.

A structured patient recruitment platform that facilitates and streamlines the candidate identification process for pharmaceutical companies and Contract Research Organizations (CRO), StuffThatWorks for Life Sciences affords its partners access to the world’s largest Real World Evidence-centric database containing over 1.2 Billion data points of consistently structured information across 750 conditions.

Recommended AI News: CyCognito Unveils ‘Exploit Intelligence’ to Accelerate Risk Remediation

Successful recruitment of patients is known to be one of the most challenging aspects of conducting clinical trials; recent research published by Nature indicates that “Just 5% of eligible patients participate in clinical research”. Barriers to patient recruitment such as identifying and contacting potential clinical trial participants, lack of patient awareness about available trials, distrust, and less-than-optimal questionnaire design stand in the way of recruitment and retention of trial subjects.

“Our mission has always been to empower patients to make their real world experience with treatments more central in the bigger picture of healthcare. There’s no better way of accomplishing that than by arming patients with big data created from their own experience,” said Yael Elish, CEO and co-founder of StuffThatWorks. “With StuffThatWorks for Life Sciences, we aim to amplify the patient voice and channel this data to bridge the communication gap between patients and pharma. By doing so, the opportunity to optimize clinical trial design, improve upon the development of therapies and better tailor care to the needs of the patient, becomes a reality – bringing us one step closer to better outcomes for all.”

Recommended AI News: Customer ‘retargeting’ on Mobile Driving 100x Increase in Sales

With searchable parameters of inclusion and exclusion criteria, the customizable Solutions Dashboard allows partners to meticulously tailor their search to pinpoint and engage their target audience for everything ranging from awareness campaigns, focus groups, and targeted surveys to clinical trials and more. An interactive map that highlights the geolocation of participants that match the campaign criteria and patient engagement dashboard all culminate to offer the ideal tool for sponsors and CROs.

Recommended AI News: Mavenir Announces Business Communications Portfolio

[To share your insights with us, please write to sghosh@martechseries.com]

The post StuffThatWorks Ushers in a New Era of Patient-Pharma Communication with the Launch of StuffThatWorks for Life Sciences appeared first on AiThority.

contract research


life sciences

digital health

big data

Markets

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending